Updated on 8 April 2015
Photo courtesy: (www.freedigitalphotos.net)
Singapore: Pfizer has named Professor Charles Reay Mackay as the new chief scientific officer for its Inflammation and Immunology Research Unit. Prof Mackay will report directly to Dr José-Carlos Gutiérrez-Ramos, PhD, group vice president of BioTherapeutics Research & Development, and will be based in Pfizer's R&D hub in Cambridge, MA.
"Prof Mackay's research has been focused on understanding the fundamental mechanisms that regulate the immune system, developing new monoclonal antibody treatments for inflammation and exploring strategies to prevent inflammatory diseases through gut microbe/epithelial barrier modulation," said Dr Gutiérrez-Ramos.
He added, "Prof Mackay brings to Pfizer a unique combination of scientific expertise, academic credentials and entrepreneurial spirit. His deep commitment to drug discovery and his unique skill set will help advance Pfizer's position as a global leader in inflammation and a collaborator of choice within the Cambridge community and beyond."
Prof Mackay has worked at the Charles Perkins Center at Sydney University, where he chaired the diabetes department. He has held biotech leadership positions at LeukoSite and Millennium Therapeutics in Cambridge, Mass, and has authored more than 160 peer-reviewed scientific publications.